Biomarkers and the Development of a Personalized Medicine Approach in Spinal Muscular Atrophy

Biomarkers and the Development of a Personalized Medicine Approach in Spinal Muscular Atrophy

Recent unprecedented advances in treatment for spinal muscular atrophy (SMA) enabled patients to access the first approved disease modifying therapy for the condition. There are however many uncertainties, regarding timing of treatment initiation, response to intervention, treatment effects and long...

Full description

Bibliographic Details
Main Authors: Didu S. T. Kariyawasam, Arlene D'Silva, Cindy Lin, Monique M. Ryan, Michelle A. Farrar
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-08-01
Series:Frontiers in Neurology
Subjects:
biomarker
spinal muscular atrophy
motor unit number estimation
compound muscle action potential
SMN2
neurofilament
Online Access:https://www.frontiersin.org/article/10.3389/fneur.2019.00898/full

Internet

https://www.frontiersin.org/article/10.3389/fneur.2019.00898/full

Similar Items